Yihuo Bio, a U.S.-based biotechnology startup, has announced plans to build research-and-development centers and factories in China before June and produce a new device for the early detection of lung cancer, China Daily reported.
According to the report, the plan is now awaiting approval from Chinese health authorities.
The report said that the device would be produced on a massive scale, based on a new cancer-detection method developed by scientists from UCLA. The method utilizes a novel technology called electric field-induced release and measurement to test saliva for epidermal gene mutations, which is a sign of lung cancer.
